Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors

Molecular Psychiatry

Volumn 9, Issue 1, 2004, Pages 35-41

  Brody, S A ^a   Dulawa, S C ^a,d   Conquet, F ^b,e   Geyer, M A ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e ADDEX PHARMACEUTICALS   (Switzerland)

Author keywords

Knockout mouse; Metabotropic glutamate; mGluR5; PPI; Prepulse inhibition; Startle

Indexed keywords

GLUTAMATE RECEPTOR 5;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; KNOCKOUT MOUSE; MALE; MOUSE; MOUSE MUTANT; MOUSE STRAIN; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSORY STIMULATION; STIMULUS RESPONSE; WILD TYPE;

ANIMALS; AUDITORY PERCEPTION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURAL INHIBITION; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA; STARTLE REACTION;

EID: 0842264953     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001404     Document Type: Article

References (38)

1. Braff DL, Geyer MA, Sensorimotor gating and schizophrenia: human and animal model studies. Arch Gen Psychiatry 1990; 47: 181-188.
2. Ison JR, Hoffman HS. Reflex modification in the domain of startle: II. The anomalous history of a robust and ubiquitous phenomenon. Psychol Bull 1983; 94: 3-17.
3. Hoffman HS, Ison JR. Reflex modification in the domain of startle: 1. Some empirical-findings and their implications for how the nervous-system processes sensory input. Psychol Rev 1980; 87: 175-189.
4. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 2001; 156: 234-258.
5. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 2001; 156: 117-154.
6. Swerdlow NR, Braff DL, Taaid N, Geyer MA. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 1994; 51: 139-154.
7. Graham FK, Putnam LE, Leavitt LA. Lead-stimulation effects on human cardiac orienting and blink reflexes. J Exp Psychol - Hum Percept Perform 1975; 104: 161-169.
8. Allen RM, Young SJ. Phencyclidine-induced psychosis. Am J Psychiatry 1978; 135: 1081-1084.
9. Karper LP, Grillon C, Abi-Saab D, Morgan CAI, Charney DS, Krystal J. The effect of ketamine on pre-pulse inhibition and attention. Schizophr Res 1995; 15: 180.
10. Mansbach RS, Geyer MA. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 1989; 2: 299-308.
11. Dulawa SC, Geyer MA. Psychopharmacology of prepulse inhibition in mice. Chin J Physiol 1996; 39: 139-146.
12. Linn GS, Javitt DC. Phencyclidine (PCP)-induced deficits of prepulse inhibition in monkeys. NeuroReport 2001; 12: 117-120.
13. Conn PJ, Patel J. The Metabotropic Glutamate Receptors. Humana Press, Inc.: Totowa, NJ, 1994.
14. Bordi F, Ugolini A. Group I metabotropic glutamate receptors: implications for brain diseases. Prog Neurobiol 1999; 59: 55-79.
15. Swerdlow NR, Geyer MA, Braff DL. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology 2001; 156: 194-215.
16. 2+ signal transduction. J Biol Chem 1992; 267: 13361-13368.
17. Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Mol Brain Res 1998; 56: 207-217.
18. Devon RS, Porteous DJ. Physical mapping of a glutamate receptor gene in relation to a balanced translocation associated with schizophrenia in a large Scottish family. Psychiatr Genet 1997; 7: 165-169.
19. Oka A, Takashima S. The up-regulation of metabotropic glutamate receptor 5 (mGluR5) in Down's syndrome brains. Acta Neuropathol 1999; 97: 275-278.
20. Chiamulera C, Epping-Jordan MP, Zocchi A, Marcon C, Cottiny C, Tacconi S et al. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci 2001; 4: 873-874.
21. Geyer MA, Swerdlow NR. Measurement of the startle response, prepulse inhibition, and habituation. In: Crawley JN, Skolnick P (eds). Current Protocols in Neuroscience. J Wiley: New York, 1998, pp. 8.7.1-8.7.15.
22. Varty GB, Walters N, Cohen-Williams M, Carey GJ. Comparison of apomorphine, amphetamine and dizocilpine disruptions of prepulse inhibition in inbred and outbred mice strains. Eur J Pharmacol 2001; 424: 27-36.
23. Braff DL, Stone C, Callaway E, Geyer MA, Click ID, Bali L. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 1978; 15: 339-343.
24. Paylor R, Crawley JN. Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacology 1997; 132: 169-180.
25. Braff DL, Grillon C, Geyer MA. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 1992; 49; 206-215.
26. Grillon C, Ameli R, Charney DS, Krystal J, Braff DL. Startle gating deficits occur across prepulse intensities in schizophrenic patients. Biol Psychiatry 1992; 32: 939-943.
27. Henry SA, Dulawa SC, Conquet F, Geyer MA. Severe disruption of prepulse inhibition (PPI) in mice lacking mGluR5. Soc Neurosci Abstr 1999; 25: 449.
28. Henry SA, Conquet F, Geyer MA. Prepulse inhibition (PPI) deficit in mGluR5 knockout mice after multiple manipulations. Soc Neurosci Abstr 2001; 27, 983.14.
29. Kinney GG, Burno M, Campbell UC, Hernandez LM, Rodriguez D, Bristow LJ et al. Metabotropic glutamate subtype 5 receptors (mGluR5) modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Ther 2003; 306: 116-123.
30. Lu YM, Jia Z, Janus C, Henderson JT, Gerlai R, Wojtowicz JM et al. Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J Neurosci 1997; 17: 5196-5205.
31. Crawley JN, Belknap JK, Collins A, Crabbe JC, Frankel W, Henderson N et al. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology 1997; 132: 107-124.
32. Willott JF. Changes in frequency representation in the auditory-system of mice with age-related hearing impairment. Brain Res 1984; 309: 159-162.
33. Grauer SM, Marquis KL. Intracerebral administration of metabotropic glutamate receptor agonists disrupts prepulse inhibition of acoustic startle in Sprague-Dawley rats. Psychopharmacology 1999; 141: 405-412.
34. Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG et al. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3. 1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 1997; 40: 528-537.
35. Schreiber R, Lowe D, Voerste A, De Vry J. LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine. Eur J Pharmacol 2000; 388: R3-R4.
36. Henry SA, Lehmann-Masten V, Gasparini F, Geyer MA, Markou A. The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 2002; 43: 1199-1209.
37. Anderson JJ, Rao SP, Rowe B, Giracello DR, Holtz G, Chapman DF et al. H-3]methoxymethyl-3-[(2-methylyl-1,3-thiazol-4-yl)ethynyl]-pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J Pharmacol Exp Ther 2002; 303: 1044-1051.
38. Spooren WP, Gasparini F, van der Putten H, Koller M, Nakanishi S, Kuhn R. Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. Eur J Pharmacol 2000; 397; R1-R2.